Vis enkel innførsel

dc.contributor.authorGansmo, Liv Beatheen_US
dc.contributor.authorBjørnslett, Merete Paulineen_US
dc.contributor.authorHalle, Mari Kyllesøen_US
dc.contributor.authorSalvesen, Helgaen_US
dc.contributor.authorRomundstad, Pål Richarden_US
dc.contributor.authorHveem, Kristianen_US
dc.contributor.authorVatten, Lars Johanen_US
dc.contributor.authorDørum, Anneen_US
dc.contributor.authorLønning, Per Eysteinen_US
dc.contributor.authorKnappskog, Stianen_US
dc.date.accessioned2018-04-25T11:58:37Z
dc.date.available2018-04-25T11:58:37Z
dc.date.issued2017-02-03
dc.PublishedGansmo LB, Bjørnslett MP, Halle MK, Salvesen H, Romundstad PR, Hveem K, Vatten LJ, Dørum A, Lønning PE, Knappskog S. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer. 2017;17:97eng
dc.identifier.issn1471-2407
dc.identifier.urihttps://hdl.handle.net/1956/17658
dc.description.abstractBackground: The del1518 (rs3730485) polymorphism is an in/del variant in the MDM2 promoter P1. The variant is in complete linkage disequilibrium with MDM2 SNP309 (rs2279744) and has previously been found associated with an increased risk of colon cancer. In this study we assessed the impact of MDM2 del1518 on risk of ovarian and endometrial cancer. Methods: Here, we genotyped del1518 in two large hospital-based series of patients diagnosed with ovarian (n = 1,385) or endometrial (n = 1,404) cancer and performed risk estimations as compared to the genotype distribution among 1,872 healthy female controls. Results: In overall analysis we observed no association between del1518 and risk of either ovarian or endometrial cancer. However, stratifying according to SNP309 status, we found the del1518 variant to be associated with a reduced risk of endometrial cancer among individuals carrying the SNP309TT genotype both in the dominant (OR = 0.64; 95% CI = 0.45 – 0.90) and the recessive model (OR = 0.80; 95% CI = 0.65 – 1.00). No such association was observed for ovarian cancer risk. Conclusion: We found the MDM2 del1518 del variant to be associated with reduced risk of endometrial cancer among individuals carrying the MDM2 SNP309TT genotype.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.subjectMDM2eng
dc.subjectDel1518eng
dc.subjectCancer riskeng
dc.subjectOvarian cancereng
dc.subjectEndometrial cancereng
dc.titleMDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risken_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2017-12-29T11:32:23Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2017 The Author(s)
dc.identifier.doihttps://doi.org/10.1186/s12885-017-3094-y
dc.identifier.cristin1470064
dc.source.journalBMC Cancer
dc.relation.projectNorges forskningsråd: 220964


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY